Accuracy and Clinical Impact of Mediastinal Lymph Node Staging with FDG–PET Imaging in Potentially Resectable Lung Cancer
- 1 February 2000
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 23 (1) , 47-52
- https://doi.org/10.1097/00000421-200002000-00014
Abstract
To determine the sensitivity, specificity, and accuracy of staging mediastinal nodal disease in potentially resectable lung cancer using fluorodeoxyglucose–positron emission tomography (FDG–PET), computed tomography (CT), or both and compare these results to surgical staging. We also assessed whether PET scanning results changed clinical management. From 1992 to 1997, 50 patients underwent CT, and PET scanning before or close to the time of surgical staging. Sensitivity, specificity, accuracy, and predictive values were then calculated based on pathology results. A retrospective review of the records was performed to determine how PET results affected clinical treatment decisions. Forty-seven of 50 patients had non–small-cell lung cancer. The prevalence of pathologically confirmed mediastinal and hilar involvement was 38%. The sensitivity, specificity, and accuracy of mediastinal disease staging were as follows: CT alone = 73%, 77%, 76%; PET alone = 73%, 94%, 87%; PET + CT = 82%, 96%, 91%, respectively. PET was more specific and accurate than CT (p = 0.025). The results of PET changed management decisions in 12 of 50 cases (24%). Using FDG–PET in conjunction with CT scanning provides the most accurate staging of mediastinal disease in lung cancer by contributing complementary information. Furthermore, PET can affect clinical decision-making and allow some patients considered unresectable a chance for resection.Keywords
This publication has 13 references indexed in Scilit:
- Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.Journal of Clinical Oncology, 1998
- Mediastinal Lymph Node Staging With FDG-PET Scan in Patients With Potentially Operable Non-small Cell Lung CancerChest, 1997
- Likelihood of Malignancy in a Solitary Pulmonary NoduleChest, 1997
- Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET)Thorax, 1997
- Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancerEuropean Respiratory Journal, 1996
- 18F-fluorodeoxyglucose PET scans in lung cancer.Thorax, 1996
- The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomographyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomographyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Thoracic Nodal Staging With PET Imaging With 18FDG in Patients With Bronchogenic CarcinomaChest, 1995
- Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.Radiology, 1994